Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026)
Grown Rogue International's (GRUSF) quarterly Cash from Financing Activities came in at $2.7 million in Q1 2026, down 41.3% year-on-year from $4.5 million in Q1 2025, and up 100.0% quarter-over-quarter from -$10136.9 billion in Q4 2025.
Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Grown Rogue International's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 41.3% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was -$10136.9 billion, a 299677216.8% decrease from a year earlier, with the FY2025 full-year figure at $9.8 million, up 117.4% from the prior year.
- Cash from Financing Activities climbed to $2.7 million in Q1 2026 per GRUSF's latest filing, from -$10136.9 billion in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $4.5 million in Q1 2025 and bottomed at -$10136.9 billion in Q4 2025.
- The 5-year median for Cash from Financing Activities is $871165.0 (2022), against an average of -$844.7 billion.
- Biggest YoY gain for Cash from Financing Activities was 34.62% in 2025; the steepest drop was 3604482049.28% in 2025.
- Year by year, Cash from Financing Activities stood at $944368.0 in 2022, then jumped by 162.2% to $2.5 million in 2023, then sank by 111.36% to -$281230.6 in 2024, then sank by 3604482049.28% to -$10136.9 billion in 2025, then jumped by 100.0% to $2.7 million in 2026.
- Per Business Quant, the three latest GRUSF Cash from Financing Activities figures stand at $2.7 million (Q1 2026), -$10136.9 billion (Q4 2025), and $4.5 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 2.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.67 Mn |
| Mar 31, 2026 | 2.67 Mn |
| Dec 31, 2025 | -10,136.91 Bn |
| Dec 31, 2025 | -10,136.91 Bn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | -281,230.64 |
| Dec 31, 2024 | -281,230.64 |
| Sep 30, 2024 | -200,531.89 |
| Sep 30, 2024 | -200,531.89 |
| Jun 30, 2024 | -683,206.97 |
| Jun 30, 2024 | -683,206.97 |
| Mar 31, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Oct 31, 2023 | 2.48 Mn |
| Oct 31, 2023 | 2.48 Mn |
| Jul 31, 2023 | 3.08 Mn |
| Jul 31, 2023 | 3.08 Mn |
| Apr 30, 2023 | -731,322.00 |
| Apr 30, 2023 | -731,322.00 |